- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16:00 | Guard Therapeutics International AB (publ) receives observation status | 32 | GlobeNewswire | On December 4, 2025, Guard Therapeutics International AB (publ) (the "Company") issued a press release with information that the Board of Directors of the Company had resolved to commence an exploratory... ► Artikel lesen | |
| 04.12. | Guard Therapeutics International AB: Guard Therapeutics Explores Strategic Alternatives | 46 | GlobeNewswire (Europe) | Guard Therapeutics (publ) ("Guard" or the "Company") today announces that the Board of Directors has resolved to commence an exploratory process regarding strategic alternatives, including identifying... ► Artikel lesen | |
| 04.12. | Guard Therapeutics International AB: Guard Therapeutics Provides Assessment of Full POINTER Study Results | 42 | GlobeNewswire (Europe) | Guard Therapeutics (public) ("Guard" or "the Company") today provides an assessment of the full results from the Phase 2b POINTER study evaluating RMC-035 in patients undergoing open-heart surgery.... ► Artikel lesen | |
| GUARD THERAPEUTICS INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 13.11. | Guard Therapeutics International AB Q3 Loss Narrows | - | RTTNews | ||
| 26.10. | Guard Therapeutics International AB: Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study | 382 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced top-line results from the company's Phase 2b POINTER study evaluating the investigational drug candidate RMC-035 as a kidney-protective therapy in patients... ► Artikel lesen | |
| 05.10. | Guard Therapeutics International AB: Guard Therapeutics Announces New Positive Efficacy Results from Secondary Analyses of the Phase 2a AKITA Study | 149 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced favorable efficacy results from additional analyses of the Phase 2a AKITA study with the investigational drug candidate RMC-035. The previously reported primary... ► Artikel lesen | |
| 11.09. | Guard Therapeutics International AB: Guard Therapeutics announces completion of data collection in Phase 2b POINTER study | 668 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced that the last patient in its ongoing Phase 2b clinical trial, POINTER, has successfully completed the final scheduled follow-up visit 90 days after surgery... ► Artikel lesen | |
| 21.08. | Guard Therapeutics International AB: Guard Therapeutics publishes interim report January-June 2025 | 171 | GlobeNewswire (Europe) | The quarter marked a key milestone with the completion of patient recruitment for our Phase 2b POINTER study - ahead of schedule. The positive final safety review reinforces confidence in the trial... ► Artikel lesen | |
| 05.06. | Guard Therapeutics International AB: Guard Therapeutics announces completion of patient enrollment in Phase 2b POINTER study | 180 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced that the last patient has been successfully enrolled in the company's ongoing Phase 2b clinical trial, POINTER, evaluating the drug candidate RMC-035 as a kidney-protective... ► Artikel lesen | |
| 27.05. | Guard Therapeutics International AB: Guard Therapeutics reports positive outcome from second planned safety review in the Phase 2b POINTER study | 216 | GlobeNewswire (Europe) | Guard Therapeutics today announced that an independent Data Safety Monitoring Committee (DSMC) has completed the second and final planned review of safety data from the ongoing Phase 2b clinical trial... ► Artikel lesen | |
| 25.03. | Guard Therapeutics International AB: Two-thirds of patients enrolled in Guard Therapeutics' Phase 2b POINTER study | 390 | GlobeNewswire (Europe) | Guard Therapeutics announced today that it has reached another key milestone in its ongoing clinical development program. Two-thirds of the approximately 160 planned patients have now been enrolled... ► Artikel lesen | |
| 14.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.03.2025 | 1.858 | Xetra Newsboard | Das Instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY wird cum Kapitalmassnahme gehandelt am 14.03.2025 und ex Kapitalmassnahme am 17.03.2025 The instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY... ► Artikel lesen | |
| 10.03. | Guard Therapeutics International AB: The Board of Directors of Guard Therapeutics has resolved on a previously announced rights issue of approximately SEK 150 million | 342 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 27.02. | Guard Therapeutics International AB: Guard Therapeutics announces positive outcome from first independent safety data review in Phase 2b POINTER study | 231 | GlobeNewswire (Europe) | Guard Therapeutics announced today that an independent Data Safety Monitoring Committee (DSMC) has completed its first planned review of safety data and has recommended that the Phase 2b clinical study... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 52,62 | -0,72 % | Novonesis (Novozymes A/S): Novonesis delivered 8% organic sales growth in the first nine months of 2025 | Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark - November 6, 2025. Novonesis delivered 8% organic sales growth... ► Artikel lesen | |
| GENMAB | 269,40 | +0,79 % | Genmab: Nach wie vor ein schwacher Ausblick | Genmab überrascht Quartal für Quartal. Viermal infolge mindestens 29 % mehr Gewinn als erwartet. Schlafen die Prognostiker Den vollständigen Artikel lesen ... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,964 | +0,87 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| VERICEL | 33,000 | +1,85 % | Vericel Corporation: Vericel Reports Third Quarter 2025 Financial Results | Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow... ► Artikel lesen | |
| MOLECULIN BIOTECH | 5,170 | +7,26 % | Moleculin Biotech, Inc.: Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal "MIRACLE" Phase 3 AML Trial on Pace for Q1 2026 | Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected range Consented subjects now across seven countries supporting the expansion of the... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 8,530 | -0,23 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,838 | -2,13 % | BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements | NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,307 | -1,60 % | MustGrow Biologics Corp.: MustGrow Reports Significant U.S. Potato Yield and Economic Performance in Large Scale Field Trials Utilizing TerraSante | Mustard-derived organic TerraSanteTM focuses on crop yields, soil and soil microbiome health, and nutrient/water use efficiencies;Large scale field trial showed 2 ton per acre yield increase with larger... ► Artikel lesen | |
| AKEBIA | 1,348 | -3,02 % | Akebia Therapeutics, Inc.: Akebia Announces Establishment of Rare Kidney Disease Pipeline | Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease... ► Artikel lesen | |
| REGENXBIO | 11,000 | -1,79 % | REGENXBIO Inc.: REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights | RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026
Pivotal trial enrollment... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,150 | -1,38 % | Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD | CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 6,350 | -3,05 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors | - City of Hope to Evaluate PEDMARK- for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors - - Initiation of Study Reflects Growing Clinical Interest in Addressing... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 3,420 | 0,00 % | AbbVie wins $56M royalty award from Revance in Botox patent infringement case | ||
| CORVUS PHARMACEUTICALS | 7,150 | -1,65 % | Corvus Pharmaceuticals stock awaits key January 2026 trial data | ||
| CARTESIAN THERAPEUTICS | 6,250 | -1,57 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grant | FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen |
Das Unternehmen GUARD THERAPEUTICS INTERNATIONAL AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,006 (+21,05 %) liegt der Kurs bei 0,032 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GUARD THERAPEUTICS INTERNATIONAL AB finden Sie auf Wallstreet Online.